Are Seizure Detection Devices Ready for Prime Time?

Area of Science:

• Neurology
• Biomedical Engineering
• Medical Devices

Background:

• Epilepsy seizure detection devices require rigorous testing and validation.
• Clinical validation in artificial environments like epilepsy monitoring units (EMUs) may be biased.
• Wearable devices offer potential for detecting seizures, including generalized tonic-clonic seizures (GTCS), and preventing sudden unexpected death in epilepsy (SUDEP).

Purpose of the Study:

• To propose standards for testing and clinical validation of seizure detection devices.
• To evaluate the real-world applicability and usability of a wearable accelerometer device for detecting bilateral tonic-clonic seizures (BTCS).
• To explore the role of wearable devices in SUDEP prevention through reliable GTCS detection and biomarker identification.

Main Methods:

• Development of a 5-phase classification system for studies on seizure detection devices, covering subjects, recordings, data analysis, alarms, and reference standards.
• A field study (phase 4) involving 71 patients using a wearable accelerometer device (Epi-Care) for BTCS detection.
• Analysis of biosignals from wearable devices for potential SUDEP biomarkers.

Main Results:

• The proposed standards provide a framework for designing, reporting, and assessing the quality of seizure detection device studies.
• The wearable accelerometer device demonstrated comparable sensitivity (90%) and false alarm rates (0.1/day) in a field study to EMU-based validation.
• Patients and caregivers reported overall satisfaction, comfort, and efficiency with the device, with 40% experiencing fewer seizure-related injuries. Device use influenced seizure diary logging in 55% of cases.
• Wearable devices can detect GTCS, potentially enabling optimized treatment, immediate caregiver intervention, and identification of SUDEP risk biomarkers.

Conclusions:

• The proposed standards enhance the quality and clarity of research on seizure detection technologies.
• The wearable accelerometer device is applicable and usable for detecting BTCS in a real-world setting, improving patient care and safety.
• Wearable device technology holds significant promise for SUDEP prevention by enabling reliable GTCS detection and identifying predictive biomarkers.